Literature DB >> 15991797

Clinical and laboratory evaluation of a new specific ELISA for intact proinsulin.

A Pfützner1, A H Pfützner, P H Kann, R Stute, M Löbig, J W Yang, J Mistry, T Forst.   

Abstract

Intact proinsulin is a marker for pancreatic beta-islet cell secretion status, and elevated levels indicate insulin resistance of type 2 diabetic patients with a high diagnostic specificity. Determination of intact proinsulin in fasting morning plasma samples can be used to establish and/or identify the optimal anti-diabetic treatment as well as to monitor a potential protective treatment effect on beta-islet cell dysfunction. For widespread use as a routine marker, simple and reliable assays must become available for measurement in clinical laboratories. This study was performed to evaluate a new ELISA method specific for intact proinsulin determination compared with a commercial chemiluminescence test. Intra-assay imprecision was determined to be 2.4 - 5.5% (inter-assay: 3.2 - 4.3%). A sample cohort derived from non-diabetic healthy subjects (66 female, 29 male, age (median, range): 37 (19-77) years) was used to calculate a reference range for non-diabetic individuals of 1.8 - 11.0 pmol/l. The comparison of samples obtained from 7 diabetic patients (2 female, 5 male, age: 66 (44-72) years) from oral glucose tolerance tests resulted in an excellent correlation between the ELISA and the chemiluminescence assay (r = 0.989; p<0.001). A sample stability investigation with different sample specimens revealed that intact proinsulin is stable for two days at room temperature in EDTA whole blood and heparin whole blood tubes without centrifugation, while serum samples should be centrifuged immediately and frozen to retain intact proinsulin concentrations. As EDTA whole blood is the routine sample specimen for determination of HbA1c, a marker frequently measured in diabetic patients, this finding underlines the practicability of analyzing intact proinsulin from the same blood specimen. In conclusion our study revealed that the new ELISA shows excellent agreement with the commonly used chemiluminescence immunoassay. The ELISA can easily be introduced into routine laboratories and does not require any further specific instrumentation. Our additional finding that intact proinsulin is stable in EDTA whole blood samples, which can be obtained from the routine.sample for HbA1c measurement, is increasing the probability of the acceptance of this marker for routine assessment of beta-cell dysfunction and insulin resistance in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15991797

Source DB:  PubMed          Journal:  Clin Lab        ISSN: 1433-6510            Impact factor:   1.138


  5 in total

1.  Elevated Intact Proinsulin Levels During an Oral Glucose Challenge Indicate Progressive ß-Cell Dysfunction and May Be Predictive for Development of Type 2 Diabetes.

Authors:  Andreas Pfützner; Iris Hermanns; Sanja Ramljak; Filiz Demircik; Anke H Pfützner; Peter H Kann; Matthias M Weber
Journal:  J Diabetes Sci Technol       Date:  2015-09-29

Review 2.  Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone.

Authors:  Andreas Pfützner; Thomas Forst
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

3.  Fasting Proinsulin Independently Predicts Incident Type 2 Diabetes in the General Population.

Authors:  Sara Sokooti; Wendy A Dam; Tamas Szili-Torok; Jolein Gloerich; Alain J van Gool; Adrian Post; Martin H de Borst; Ron T Gansevoort; Hiddo J L Heerspink; Robin P F Dullaart; Stephan J L Bakker
Journal:  J Pers Med       Date:  2022-07-12

4.  Pancreatic β-cell dysfunction and risk of new-onset diabetes after kidney transplantation.

Authors:  Dorien M Zelle; Eva Corpeleijn; Jolijn Deinum; Ronald P Stolk; Rijk O B Gans; Gerjan Navis; Stephan J L Bakker
Journal:  Diabetes Care       Date:  2013-02-01       Impact factor: 19.112

5.  Preanalytical, analytical, and computational factors affect homeostasis model assessment estimates.

Authors:  Susan E Manley; Stephen D Luzio; Irene M Stratton; Tara M Wallace; Penelope M S Clark
Journal:  Diabetes Care       Date:  2008-06-05       Impact factor: 19.112

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.